What is LongevityOne?

LongevityOne is a global platform dedicated to curing human aging. We consolidate advanced research, emerging technology, and unified data to accelerate innovation in the longevity space. Our mission is to serve scientists, bio-hackers, and advocates with trustworthy resources and collaborative tools.

Who founded LongevityOne?

LongevityOne was founded by Michael Peres, a serial entrepreneur and biomedical researcher with a background in Mathematics, Computer Science, and Jewish Studies. He is currently pursuing Biomedical Engineering to strengthen the technical foundation of LongevityOne’s work. Learn more about him at michaelperes.com.

What makes LongevityOne different?

We don’t just report on breakthroughs — we unify them. LongevityOne acts as a central repository where research, news, tools, and contributors converge. By removing silos in the aging research ecosystem, we accelerate progress toward reversing age-related decline.

Who is LongevityOne for?

Our platform is built for:Researchers in biotechnology, genetics, and agingMedical professionals and institutionsBio-hackers and health optimizersInvestors in life-extension technologiesPublic advocates for healthy aging

What are your long-term goals?

Our core objective is to contribute to the development of a foundational cure for aging. We aim to reshape the human experience of aging by supporting breakthrough research, increasing public understanding, and fostering international collaboration over the next 15 years.

How do I get involved?

Whether you’re a researcher, journalist, developer, or longevity enthusiast, we welcome your participation. Email us at contact@longevityone.org to explore partnerships, media opportunities, or to join our contributor network.

Contributor+

Landmark Study Shows Ozempic May Treat This Deadly Liver Disease

SciTechDaily
May 27, 2025

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers from Virginia Commonwealth University (VCU) and King’s College London suggests that semaglutide, the active substance found in medications like Ozempic and Wegovy, can halt and potentially reverse a common liver disease affecting millions globally. The research […]

Full article can be found at: https://scitechdaily.com/landmark-study-shows-ozempic-may-treat-this-deadly-liver-disease/

Key Terms

Categories: Contributor+

SciTechDaily

SciTechDaily offers the best intelligent, informed science and technology coverage and analysis you can find on a daily basis, sourcing a huge range of great writers and excellent research institutes. It was founded in 1998 by Vicki Hyde, a friend of Denis Dutton (of Arts & Letters Daily fame) and was essentially a sister site to ALDaily.com. The idea was to link to the most thought-provoking, well researched online items in the world of science and technology. (Originally, this site was known as SciTech Daily Review, but it was simplified to SciTechDaily in 2011. The address has always remained SciTechDaily.com.)